I want to point out that we have a grreater than 20 year lookback period with TNF inhibition that suggests that they do not appear to increase the risk of lymphoma over the control RA database, only the SEER database. Thus, Dr Singh pointing out the label warning on TNFs for cancer does not pertain to the same data found in the ORAl trial. Mechanistically , it can not be ignored that there is a stronger change to the lipid profile with Tofa than with tofa, and although this has previously been downplayed as " no endpoint effect " is seen , we clearly now have at least a possible link between an unfavorable lipid change and MACE events. Who does the get compensation from as an advisor.